Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

Simple item page
dc.citation.firstpage3655
dc.citation.issueNumber26
dc.citation.journalTitleVaccine
dc.citation.lastpage3663
dc.citation.volumeNumber40
dc.contributor.authorPollet, Jeroen
dc.contributor.authorStrych, Ulrich
dc.contributor.authorChen, Wen-Hsiang
dc.contributor.authorVersteeg, Leroy
dc.contributor.authorKeegan, Brian
dc.contributor.authorZhan, Bin
dc.contributor.authorWei, Junfei
dc.contributor.authorLiu, Zhuyun
dc.contributor.authorLee, Jungsoon
dc.contributor.authorKundu, Rahki
dc.contributor.authorAdhikari, Rakesh
dc.contributor.authorPoveda, Cristina
dc.contributor.authorJose Villar, Maria
dc.contributor.authorRani Thimmiraju, Syamala
dc.contributor.authorLopez, Brianna
dc.contributor.authorGillespie, Portia M.
dc.contributor.authorRonca, Shannon
dc.contributor.authorKimata, Jason T.
dc.contributor.authorReers, Martin
dc.contributor.authorParadkar, Vikram
dc.contributor.authorHotez, Peter J.
dc.contributor.authorElena Bottazzi, Maria
dc.contributor.orgJames A. Baker III Institute for Public Policy
dc.date.accessioned2022-06-08T15:58:47Z
dc.date.available2022-06-08T15:58:47Z
dc.date.issued2022
dc.description.abstractWe conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General ofIndia. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum + CpG. We also evaluated mice immunized with RBD/alum + CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum + CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum + CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2, including variants of concern.
dc.identifier.citationPollet, Jeroen, Strych, Ulrich, Chen, Wen-Hsiang, et al.. "Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern." <i>Vaccine,</i> 40, no. 26 (2022) Elsevier: 3655-3663. https://doi.org/10.1016/j.vaccine.2022.05.007.
dc.identifier.digital1-s2-0-S0264410X22005771-main
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2022.05.007
dc.identifier.urihttps://hdl.handle.net/1911/112444
dc.language.isoeng
dc.publisherElsevier
dc.rightsThis is an open access article under the CC BY license
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleReceptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2-0-S0264410X22005771-main.pdf
Size:
1.35 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Rice Coronavirus Research